Phase II study of Docetaxel, Carboplatin, and Trastuzumab (THC) as first-line treatment in patients with HER-2 amplified advanced breast cancer. Changes in circulating tumor cells (CTC), total plasma DNA and circulating HER-2 ECD

✍ Scribed by L. Dirix; Benoy; A. Prové; H. Elst; J. Vandebroeck; H. Wuyts; M. Philips; I. Deleu; P. Van Dam; P. Vermeulen

• Book ID: 118624686
• Publisher: Elsevier Science
• Year: 2006
• Tongue: English
• Weight: 119 KB
• Volume: 4
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(06)80408-8